

PECEIVED

JAN 2 1 2004

TECH CENTER 1800/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Padigaru, et al

EXAMINER: James Martinell

SERIAL NUMBER: 09/964,956

ART UNIT: 1631

FILING: DATE:

September 26, 2001

FOR:

NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

BOX IDS

Assistant Commissioner of Patents

Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (3 pages) in duplicate;
- 3. Copies of Cited references C1- C45 and;
- 4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No. Cura 424 (21402-124) A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully resquested to contact the undersigned at 203/974-6303, New Haven, Connecticut.

Respectfully submitted,

Date: January 13, 2004

Yahwak, Reg. No. 26,824

CultaGen Corporation c/o

555 Long Wharf Drive New Haven, CT 06511

Tel: (203) 974-6303 Fax: (203) 401-3351



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Padigaru, et al.

EXAMINER: Not Yet Assigned

SERIAL NUMBER: 09/964,956

ART UNIT: 1631

FILING DATE:

September 26, 2001

FOR:

NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

BOX IDS

Assistant Commissioner of Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R.§§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R.§1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs, the enclosed form PTO-1449 to evidence that the cited information has been fully considered by Patent and Trademark Office during the examination of this application.

By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search

performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56(b); and (3) the information cited in the Statement is, or considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statement by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 502648, Reference No.Cura 424 (21402-124).

Respectfully submitted,

Date: January 13, 2004

George Yalwak, Reg. No. 26,824 c/o Cura Gen Corporation

555 Long Wharf Drive New Haven, CT 06511

Tel: (203) 974-6303 Fax: (203) 401-3351

Expr ss Mail No. El#######US

Date of Deposit: Please type a plus sign (+) in this box

+	

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

fied Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/964,956
Filing Date	9/26/01
First Named Inventor	Padigaru
Group Art Unit	1631
Examiner Name	James Martinell
Attorney Docket Number	21402-124 Cura 424

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1				

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Exam Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
	C1	GenBank Accession Number: AAK54730 (21-MAY-2001).	
	C2	GenBank Accession Number: AAL54730 (27-MAR-2003).	
	СЗ	GenBank Accession Number: AB020655 (16-JUN-1999).	
	C4	GenBank Accession Number: AB023166 (16-JUN-1999).	
	C5	GenBank Accession Number: AC002563 (26-SEP-1997).	
	C6	GenBank Accession Number: AF086824 (11-NOV-1998).	
	C7	GenBank Accession Number: AF169411 (19-SEP-2000).	
	C8	GenBank Accession Number: AF170701 (09-NOV-1999).	
	C9	GenBank Accession Number: AF326591 (19-FEB-2001).	
	C10	GenBank Accession Number: AF338650 (22-MAR-2001).	
	C11	GenBank Accession Number: AF369900 (21-MAY-2001).	
	C12	GenBank Accession Number: AK026427 (13-SEP-2003).	
	C13	GenBank Accession Number: BAA96055 (05-JUL-2002).	
	C14	GenBank Accession Number: BAB13376 (10-MAY-2002).	
	C15	GenBank Accession Number: CAB65788 (11-JAN-2000).	
	C16	GenBank Accession Number: CAC32456 (23-FEB-2001).	
	C17	GenBank Accession Number: D86949 (31-MAR-2000).	
	C18	GenBank Accession Number: M75867 (31-DEC-1994).	
-	C19	GenBank Accession Number: M92076 (27-APR-1993).	
	C20	GenBank Accession Number: NP_033182 (24-DEC-2003).	
•	C21	GenBank Accession Number: NP_115605 (23-DEC-2003).	

D-44	D	
Date of	Deposit:	
- u.o o.	- op oo	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
	C22	GenBank Accession Number: O14578 (15-JUN-2002).		
	C23	GenBank Accession Number: 075882 (15-JUN-2002). JAN 1 6 2004 o.		
	C24	GenBank Accession Number: 094933 (15-JUN-2002). GenBank Accession Number: 094991 (15-JUN-2002). SWALL (SPTR) Accession Number: Q9BX97 (1-JUN-2001)		
	C25	GenBank Accession Number: 094991 (15-JUN-2002).		
	C26	SWALL (SPTR) Accession Number: Q9BX97 (1-JUN-2001).		
	C27	SWALL (SPTR) Accession Number: Q9H5Y7 (1-MAR-2001).		
	C28	GenBank Accession Number: Q9QYS2 (15-SEP-2003).		
	C29	GenBank Accession Number: Q9WU60 (15-JUN-2002).		
	C30	GenBank Accession Number: T46279 (04-FEB-2000).		
	C31	GenBank Accession Number: XP_010150 (13-MAY-2002).		
	C32	GenBank Accession Number: XP_045786 (28-APR-2003).		
	C33	Adams, M. D. (1996). "Serial analysis of gene expression: ESTs get smaller." Bioessays 18(4): 261-2.		
	C34	Alderborn, A., A. Kristofferson, et al. (2000). "Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing." Genome Res 10(8): 1249-58.		
	C35	Arnold, P. M., J. Y. Ma, et al. (2000). "Selective developmental regulation of gene expression for insulin-like growth factor-binding proteins in mouse spinal cord." Spine 25(14): 1765-70.		
1	C36	Bonen, A. (2000). "Lactate transporters (MCT proteins) in heart and skeletal muscles." Med Sci Sports Exerc 32(4): 778-89.		
	C37	Boultwood, J., K. Rack, et al. (1991). "Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion." Proc Natl Acad Sci U S A 88(14): 6176-80.		
	C38	De Ferrari, G. V. and N. C. Inestrosa (2000). "Wnt signaling function in Alzheimer's disease." Brain Res Brain Res Rev 33(1): 1-12.		
	C39	Fraser, P. E., G. Yu, et al. (2001). "Presenilin function: connections to Alzheimer's disease and signal transduction." Biochem Soc Symp 67: 89-100.		
	C40	Jezior, J. R., J. D. Brady, et al. (2001). "Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels." Br J Pharmacol 134(1): 78-87.		
	C41	Kone, B. C. (2000). "Protein-protein interactions controlling nitric oxide synthases." Acta Physiol Scand 168(1): 27-31.		
	C42	Murakami, Y., F. Suto, et al. (2001). "Differential expression of plexin-A subfamily members in the mouse nervous system." Dev Dyn 220(3): 246-58		
1	C43	Rohm, B., A. Ottemeyer, et al. (2000). "Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A." Mech Dev 93(1-2): 95-104.		
	C44	Walsh, S. V., A. M. Hopkins, et al. (2001). "Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia." Gastroenterology 121(3): 566-79.		
	C45	Wassink, T. H., J. Piven, et al. (2001). "Evidence supporting WNT2 as an autism susceptibility gene." Am J Med Genet 105(5): 406-13.		

* a copy of	thisreference is not provided as it was	previously cited by or submitted to the office in a prior application.
Serial No.	, filed	, and relied upon for an earlier filing date under
35 U.S.C.	120 (continuation, continuation-in-part	, and divisional applications).

Examiner Signature	Date Considered	

EXAMINER: Initial if reference consider d, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADOCS: 1177824.1 (p8tc01!.doc)

